Development of Clopidogrel Polymeric Nanoparticles with Sustained Release and Improved Bioavailability for the Treatment of Myocardial Infarction

Key Points

• Improved bioavailability of clopidogrel increases therapeutic efficacy in myocardial infarction, suggesting better outcomes.
• Bioavailability improved by 30% with polymeric nanoparticles, enhancing drug delivery and efficacy.
• Development of clopidogrel polymeric nanoparticles features sustained release for prolonged therapeutic effect.
• Potential for clinical application is significant, warranting further investigation for safety and effectiveness.